文献速递白血病淋巴瘤

儿童肿瘤协作组AALL1231试验:在新诊断T细胞急性淋巴细胞白血病和淋巴瘤中测试硼替佐米的III期临床试验

Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
PubMed 文献 · J Clin Oncol · 2022-03-10

AALL1231是一项III期随机试验,纳入824例新诊断T-ALL/T-LL患者,随机接受改良augmented BFM方案联合或不联合硼替佐米。硼替佐米组T-LL患者的4年EFS和OS显著改善,T-ALL患者无显著差异,且未增加毒性;系统治疗强化使超过90%的T-ALL患者免于预防性颅脑放疗且未增加复发。

要点

  • T-LL患者接受硼替佐米后4年EFS为86.4%±4.0% vs 76.5%±5.1%(P=.041),OS为89.5%±3.6% vs 78.3%±4.9%(P=.009)。
  • T-ALL患者硼替佐米组与非硼替佐米组的4年EFS(83.8%±2.1% vs 80.1%±2.3%,P=.131)和OS(88.3%±1.8% vs 85.7%±2.0%,P=.085)无显著差异。
  • AALL1231中仅9.5%患者计划接受颅脑放疗,而未接受放疗者与AALL0434接受放疗者相比EFS(P=.412)和OS(P=.600)无统计学差异。

核心结论

  • 在AALL1231方案基础上加用硼替佐米可显著改善T-LL患者的EFS和OS。
  • 系统治疗强化使超过90%的T-ALL患者免于颅脑放疗且未增加复发。

研究设计与样本

  • 儿童肿瘤协作组III期随机临床试验AALL1231,2014年至2017年纳入824例合格且可评估的新诊断T-ALL/T-LL儿童及年轻成人。
  • 患者随机接受改良augmented Berlin-Frankfurt-Münster化疗方案,在诱导和延迟强化期间联合或不联合硼替佐米。
  • 对前驱试验AALL0434所用augmented BFM骨架进行多项修改,包括使用地塞米松替代泼尼松,并增加两剂培门冬酶,以期在多数患者中消除颅脑放疗。

主要发现

  • A组(无硼替佐米)vs B组(硼替佐米)的4年EFS为80.1%±2.3% vs 83.8%±2.1%(P=.131),4年OS为85.7%±2.0% vs 88.3%±1.8%(P=.085)。
  • T-LL患者接受硼替佐米后4年EFS为86.4%±4.0% vs 76.5%±5.1%(P=.041),4年OS为89.5%±3.6% vs 78.3%±4.9%(P=.009)。
  • 硼替佐米未观察到超额毒性。
  • AALL0434中90.8%的T-ALL患者接受了颅脑放疗;AALL1231中9.5%的患者计划接受颅脑放疗。
  • 比较AALL0434接受颅脑放疗与AALL1231未接受颅脑放疗的可比患者,EFS(P=.412)和OS(P=.600)无统计学差异。

关键数值与推荐

  • T-LL患者4年EFS:硼替佐米组86.4%±4.0% vs 无硼替佐米组76.5%±5.1%(P=.041)。
  • T-LL患者4年OS:硼替佐米组89.5%±3.6% vs 无硼替佐米组78.3%±4.9%(P=.009)。
  • T-ALL患者4年EFS:硼替佐米组83.8%±2.1% vs 无硼替佐米组80.1%±2.3%(P=.131)。
  • T-ALL患者4年OS:硼替佐米组88.3%±1.8% vs 无硼替佐米组85.7%±2.0%(P=.085)。
  • AALL0434中90.8%的T-ALL患者接受颅脑放疗,AALL1231中9.5%的患者计划接受颅脑放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To improve the outcomes of patients with T-cell acute lymphoblastic leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome inhibitor bortezomib was examined in the Children's Oncology Group phase III clinical trial AALL1231, which also attempted to reduce the use of prophylactic cranial radiation (CRT) in newly diagnosed T-ALL. PATIENTS AND METHODS: Children and young adults with T-ALL/T-LL were randomly assigned to a modified augmented Berlin-Frankfurt-Münster chemotherapy regimen with/without bortezomib during induction and delayed intensification. Multiple modifications were made to the augmented Berlin-Frankfurt-Münster backbone used in the predecessor trial, AALL0434, including using dexamethasone instead of prednisone and adding two extra doses of pegaspargase in an attempt to eliminate CRT in most patients. RESULTS: AALL1231 accrued 824 eligible and evaluable patients from 2014 to 2017. The 4-year event-free survival (EFS) and overall survival (OS) for arm A (no bortezomib) versus arm B (bortezomib) were 80.1% ± 2.3% versus 83.8% ± 2.1% (EFS, P = .131) and 85.7% ± 2.0% versus 88.3% ± 1.8% (OS, P = .085). Patients with T-LL had improved EFS and OS with bortezomib: 4-year EFS (76.5% ± 5.1% v 86.4% ± 4.0%; P = .041); and 4-year OS (78.3% ± 4.9% v 89.5% ± 3.6%; P = .009). No excess toxicity was seen with bortezomib. In AALL0434, 90.8% of patients with T-ALL received CRT. In AALL1231, 9.5% of patients were scheduled to receive CRT. Evaluation of comparable AALL0434 patients who received CRT and AALL1231 patients who did not receive CRT demonstrated no statistical differences in EFS (P = .412) and OS (P = .600). CONCLUSION: Patients with T-LL had significantly improved EFS and OS with bortezomib on the AALL1231 backbone. Systemic therapy intensification allowed elimination of CRT in more than 90% of patients with T-ALL without excess relapse.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Teachey DT, Devidas M, Wood BL, et al. Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma. J Clin Oncol. 2022. PMID: 35271306. doi:10.1200/JCO.21.02678

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。